Skip to main content

Advertisement

SpringerLink
Log in

Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET

  • Review Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Multiple endocrine neoplasia (MEN) type 2 syndromes are autosomal dominant clinical associations characterized by a common clinical feature, medullary thyroid carcinoma (MTC). The ability to accurately predict the risk by genetic RET proto-oncogene analysis has resulted in the active follow-up of children at risk for developing early metastatic tumours and which can be prevented by prophylactic thyroidectomy. The C634 and M918T mutations (associated with MEN2A and MEN2B, respectively) are particularly associated with early aggressive behavior and distant metastatic spread requiring early intervention. RET is known to be involved in cellular signalling processes during development and controls the survival, proliferation, differentiation and migration of the enteric nervous system (ENS) progenitor cells, as well as the survival and regeneration of sympathetic neural and kidney cells. The centrality of RET in the etiology of both MEN2 and HSCR is now well established with fairly consistent associations existing between RET genotype and phenotype in MEN2. The relationship between Hirschsprung’s disease (HSCR) MEN2 syndromes appears to be a highly significant one, sharing a common etiological factor in the RET proto-oncogene. It is now well accepted that most HSCR arises from loss of function, RET mutations, RET haploinsufficiency or RET polymorphisms and haplotypes of the RET promotor region. MEN2 syndromes result from gene up regulation due to germline activating mutations in the RET proto-oncogene (1:500,000). MTC is mostly associated with variations in the 5 cysteine RET radicals and codon-risk management protocols are of considerable value but not infallible. Oncogenic RET mutations may, however, vary between specific population groups. RET analysis in MEN has revolutionized the management of children of MEN2 and allowed surgical prediction and prophylaxis to take place. We discuss the role of genetic testing and possible guidelines for the management of patients from MTC families. The future appears full of promise and the current evaluation of RET-targeting tyrosine kinase and other inhibitors are of considerable interest in the management of these conditions

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216–222

    PubMed  Google Scholar 

  2. Akhand AA, Ikeyama T, Akazawa S, Kato M, Hossain K, Takeda K, Suzuki H, Takahashi M, Nakashima I (2002) Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase. Biochem Biophys Res Commun 292(4):826–831

    PubMed  CAS  Google Scholar 

  3. Antinolo G, Marcos I, Fernandez RM, Romero M, Borrego S (2002) A novel germline point mutation, c.2304 G–>T, in codon 768 of the RET proto-oncogene in a patient with medullary thyroid carcinoma. Am J Med Genet 110(1):85–87

    PubMed  Google Scholar 

  4. Arighi E, Popsueva A, Degl’Innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, Sariola H (2004) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung’s disease. Mol Endocrinol 18(4):1004–1017

    PubMed  CAS  Google Scholar 

  5. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15(3):1613–1619

    PubMed  CAS  Google Scholar 

  6. Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, Priolo M, Thompson H, Bocciardi R, Romeo G, Ballabio A, Ceccherini I (1999) Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet 64(4):1216–1221

    PubMed  CAS  Google Scholar 

  7. Ball DW (2007) Medullary thyroid cancer: therapeutic targets and molecular markers.(Curr Opin Oncol 19(1):18–23

    PubMed  CAS  Google Scholar 

  8. Barlow A, de Graaff E, Pachnis V (2003) Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET. Neuron 40(5):905–916

    PubMed  CAS  Google Scholar 

  9. Blank E, Neerhout RC, Burry KA (1978) Congenital mesoblastic nephroma and polyhydramnios. JAMA 240:1504–1505

    PubMed  CAS  Google Scholar 

  10. Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF (1996) Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 78(9):1996–2003

    PubMed  CAS  Google Scholar 

  11. Bolande RP (1974) The neurocristopathies, a unifying concept of disease arising in neural crest maldevelopment. Hum Pathol 5:409–429

    Google Scholar 

  12. Bolk S, Pelet A, Hofstra RM, Angrist M, Salomon R, Croaker D, Buys CH, Lyonnet S, Chakravarti A (2000) A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc Natl Acad Sci USA 97(1):268–273

    PubMed  CAS  Google Scholar 

  13. Bonnet JP, Till M, Edery P, Attie T, Lyonnet S (1996) Waardenburg-Hirschsprung disease in two sisters: a possible clue to the genetics of this association. Eur J Pediatr Surg 6:245–248

    PubMed  CAS  Google Scholar 

  14. Borrego S, Fernandez RM, Dziema H, Japon MA, Marcos I, Eng C, Antinolo G (2002) Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer. Thyroid 12(11):1017–1022

    PubMed  CAS  Google Scholar 

  15. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G (1998) Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 83(9):3361–3364

    PubMed  CAS  Google Scholar 

  16. Borrego S, Fernandez RM, Dziema H, Niess A, Lopez-Alonso M, Antinolo G, Eng C (2003) Investigation of germline GFRA4 mutations and evaluation of the involvement of GFRA1, GFRA2, GFRA3, and GFRA4 sequence variants in Hirschsprung disease. J Med Genet 40(3):e18

    PubMed  CAS  Google Scholar 

  17. Borst MJ, VanCamp JM, Peacock ML, Decker RA (1995) Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung’s disease. Surgery 117(4):386–391

    PubMed  CAS  Google Scholar 

  18. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671

    PubMed  CAS  Google Scholar 

  19. Brooks AS, Breuning MH, Osinga J, vd Smagt JJ, Catsman CE, Buys CH, Meijers C, Hofstra RM (1999) A consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-Shprintzen syndrome). J Med Genet 36(6):485–489

    PubMed  CAS  Google Scholar 

  20. Burzynski GM, Nolte IM, Osinga J, Ceccherini I, Twigt B, Maas S, Brooks A, Verheij J, Plaza Menacho I, Buys CH, Hofstra RM (2004) Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2. Eur J Hum Genet 12(8):604–612

    PubMed  CAS  Google Scholar 

  21. Butter A, Gagne J, Al Jazaeri A, Emran MA, Deal C, St Vil D (2007) Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung’s disease. J Pediatr Surg 42(1):203–206

    PubMed  Google Scholar 

  22. Carlomagno F, De Vita G, Berlingieri MT, de Franciscis V, Melillo RM, Colantuoni V, Kraus MH, Di Fiore PP, Fusco A, Santoro M (1996) Molecular heterogeneity of RET loss of function in Hirschsprung’s disease. EMBO J 15(11):2717–2725

    PubMed  CAS  Google Scholar 

  23. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M (2006) The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57(3):391–395

    Google Scholar 

  24. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55(6):1076–1082

    PubMed  CAS  Google Scholar 

  25. Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S (1996) C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. J Clin Endocrinol Metab 81(7):2731–2733

    PubMed  CAS  Google Scholar 

  26. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M (1998) Dual effect on the RET receptor of MEN2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17(22):2851–2861

    PubMed  CAS  Google Scholar 

  27. Costantini F, Shakya R. (2006) GDNF/Ret signaling and the development of the kidney. Bioessays 28(2):117–127

    PubMed  CAS  Google Scholar 

  28. de Groot JW, Links TP, Rouwe CW, van der Wal JE, Hofstra RM, Plukker JT (2006) Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature. Ned Tijdschr Geneeskd 150(6):311–318

    PubMed  Google Scholar 

  29. Decker RA, Peacock ML (1998) Occurrence of MEN2a in familial Hirschsprung’s disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 33(2):207–214

    PubMed  CAS  Google Scholar 

  30. Decker RA, Peacock ML, Watson P (1998) Hirschsprung disease in MEN2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 7(1):129–134

    PubMed  CAS  Google Scholar 

  31. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr (1993) Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 2(7):851–856

    PubMed  CAS  Google Scholar 

  32. Dralle H, Ukkat J, Brauckhoff M, Gimm O, Machens A (2004) Consortia experiences—can we cure MTC? J Intern Med 255(6):698–699

    Google Scholar 

  33. Drosten M, Putzer BM (2003) Gene therapeutic approaches for medullary thyroid carcinoma treatment. J Mol Med 81(7):411–419

    PubMed  CAS  Google Scholar 

  34. Dvorakova S, Dvorakova K, Malikova M, Skaba R, Vlcek P, Bendlova B. (2005) A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung’s disease. J Pediatr Surg 40(6):e1-6

    PubMed  Google Scholar 

  35. Edery P, Lyonnet S, Mulligan L et al (1994) Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 367:378–380

    PubMed  CAS  Google Scholar 

  36. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA (1995) A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10(3):509–513

    PubMed  CAS  Google Scholar 

  37. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3(2):237–241

    PubMed  CAS  Google Scholar 

  38. Fernandez RM, Antinolo G, Eng C, Borrego S (2003) The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mutat 22(5):412–415

    PubMed  CAS  Google Scholar 

  39. Fernandez RM, Antinolo G, Eng C, Borrego S (2003) The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mutat 22(5):412–415

    PubMed  CAS  Google Scholar 

  40. Fitze G (2004) Management of patients with hereditary medullary thyroid carcinoma. Eur J Pediatr Surg 14(6):375–383

    PubMed  CAS  Google Scholar 

  41. Fitze G, Saeger HD, Roesner D, Schackert HK (2004) Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene. Klin Padiatr 216(5):270–276

    PubMed  CAS  Google Scholar 

  42. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155(2):229–236

    PubMed  CAS  Google Scholar 

  43. Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M (1999) Two distinct mutations of the RET receptor causing Hirschsprung’s disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol Genet 8(11):1989–1999

    PubMed  CAS  Google Scholar 

  44. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 79(3):564–573

    PubMed  CAS  Google Scholar 

  45. Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H (2004) Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 28(12):1312–1316

    PubMed  Google Scholar 

  46. Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I (2005) A common haplotype at the 5′ end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat 25(2):189–195

    PubMed  CAS  Google Scholar 

  47. Gujral TS, Mulligan LM (2006) Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann NY Acad Sci 1073:234–240

    PubMed  CAS  Google Scholar 

  48. Guyetant S, Blechet C, Saint-Andre JP (2006) C-cell hyperplasia. Ann.Endocrinol (Paris) 67(3):190–197

    CAS  Google Scholar 

  49. Hazard JB, Hawk WA, Crile G Jnr (1959) Medullary (solid) carcinoma of the thyroid:a clinicopathologic entity. J Clin Endocrinol Metab 19:152–161

    PubMed  CAS  Google Scholar 

  50. Inoue K, Shimotake T, Inoue K, Tokiwa K (1999) Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. J Pediatr Surg 34(10):1552–1554

    PubMed  CAS  Google Scholar 

  51. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M (1997) Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res 57(14):2870–2872

    PubMed  CAS  Google Scholar 

  52. Iwashita T, Murakami H, Asai N, Takahashi M (1996) Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 5(10):1577–1580

    PubMed  CAS  Google Scholar 

  53. Kebebew E, Clark OH (2000) Medullary thyroid cancer. Curr Treat Options.Oncol 1(4):359–367

    PubMed  CAS  Google Scholar 

  54. Khan AH, Desjardin JG, Gregoire H, Seidman E (1987) Gastrointestinal manifestations of the Sipple syndrome in children. J Pediatr Surg 22:719–723

    PubMed  CAS  Google Scholar 

  55. Kjaer S, Ibanez CF (2003) Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem 278(48):47898–47904

    PubMed  CAS  Google Scholar 

  56. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibanez CF, McDonald NQ (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281(44):33577–33587

    PubMed  CAS  Google Scholar 

  57. Lantieri F, Griseri P, Puppo F, Campus R, Martucciello G, Ravazzolo R, Devoto M, Ceccherini I. (2006) Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derived from a single ancestral combination of alleles. Ann Hum Genet 70(Pt 1):12–26

    PubMed  CAS  Google Scholar 

  58. Luo Y, Barone V, Seri M, Bolino A, Bocciardi R, Ceccherini I, Pasini B, Tocco T, Lerone M, Cywes S, Moore S, Vanderwinden JM, Abramowicz MJ, Kristofferson U, Hamel B, Martucciello G, Romeo G (1994) Heterogeneity of mutations of the RET proto-oncogene in autosomal dominant HSCR. Eur J Hum Genet 2:272–280

    Google Scholar 

  59. Luo Y, Ceccherini I, Pasini B, et al (1993) Close linkage with the RET proto-oncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet. 2:1803–1808

    PubMed  CAS  Google Scholar 

  60. Machens A, Schneyer U, Holzhausen HJ, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90(4):2029–2034

    PubMed  CAS  Google Scholar 

  61. Machens A, Dralle H (2006) DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery 139(3):279–282

    PubMed  Google Scholar 

  62. Machens A, Dralle H (2006) Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 247(1–2):34–40

    PubMed  CAS  Google Scholar 

  63. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H (2001) Genotype–phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86(3):1104–1109

    PubMed  CAS  Google Scholar 

  64. Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134(3):425–431

    PubMed  Google Scholar 

  65. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H (2005) Advances in the management of hereditary medullary thyroid cancer. J Inter Med 257(1):50–59

    CAS  Google Scholar 

  66. Martuciello G, Bicocci MP, Dodero P, Lerone M, Silengo-Cirillo M, Puliti A, Gimelli G (1992) Total colonic aganglionosis associated with intestitial deletion of the long arm of chromosome 10. Pediatr Surg Int 7(4):308–310

    Google Scholar 

  67. Moore SW, Appfelstaedt J, Zaahl MG (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg 42(2):326–332

    PubMed  Google Scholar 

  68. Moore SW, Appfelstaedt J, Zaahl MG (2007) Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J.Pediatr.Surg 42(2):326–332

    PubMed  Google Scholar 

  69. Mulligan LM, Eng C, Healey CS, Ponder MA, Feldman GL, Li P, Jackson CE, Ponder BA. (1994) A de novo mutation of the RET proto-oncogene in a patient with MEN2A. Hum Mol Genet 3(6):1007–1008

    PubMed  CAS  Google Scholar 

  70. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428):458–460

    PubMed  CAS  Google Scholar 

  71. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M et al (1995) Genotype–phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238(4):343–346

    Article  PubMed  CAS  Google Scholar 

  72. Musholt PB, Musholt TJ, Goodfellow PJ, Zehnbauer BA, Wells SA, Moley JF (1997) “Cold” single-strand conformational variants for mutation analysis of the RET proto-oncogene. Surgery 122(2):363–370

    PubMed  CAS  Google Scholar 

  73. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57(9):1690–1694

    PubMed  CAS  Google Scholar 

  74. Nishikawa M, Murakumo Y, Imai T, Kawai K, Nagaya M, Funahashi H, Takahashi M (2003) Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung’s disease. Eur J Hum Genet 11(5):364–368

    PubMed  CAS  Google Scholar 

  75. Pakarinen MP, Rintala RJ, Koivusalo A, Heikkinen M, Lindahl H, Pukkala E (2005) Increased incidence of medullary thyroid carcinoma in patients treated for Hirschsprung’s disease. J Pediatr Surg 40(10):1532–1534

    PubMed  Google Scholar 

  76. Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Pansini G, Trasforini G, degli Uberti EC (2002) RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. Surgery 131(4):373–381

    PubMed  Google Scholar 

  77. Passarge E (1967) The genetics of Hirschsprung’s disease. N Engl J Med 276:138–143

    Article  PubMed  CAS  Google Scholar 

  78. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG (2002) The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 22(20):7351–7363

    PubMed  CAS  Google Scholar 

  79. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Grynberg E, Yakobson E, Lapidot M (1997) Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung’s disease suggesting a role for imprinting. Hum Mutat 10(2):155–159

    PubMed  CAS  Google Scholar 

  80. Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F (2006) Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72(4):405–414

    PubMed  CAS  Google Scholar 

  81. Pingault V, Bondurand N, Kuhlbrodt K, Goerich DE, Prehu MO, Puliti A, Herbarth B, Hermans-Borgmeyer I, Legius E, Matthijs G, Amiel J, Lyonnet S, Ceccherini I, Romeo G, Smith JC, Read AP, Wegner M, Goossens M (1998) SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 18(2):171–173

    PubMed  CAS  Google Scholar 

  82. Pinna G, Orgiana G, Riola A, Ghiani M, Lai ML, Carcassi C, Mariotti S (2007) RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17(2):101–104

    PubMed  CAS  Google Scholar 

  83. Rakover Y, Dharan M, Luboshitsky R (1994) Hirschsprung’s disease associated with isolated familial medullary carcinoma of the thyroid. J Pediatr Endocrinol 7(4):373–377

    PubMed  CAS  Google Scholar 

  84. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G (1998) Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 243(6):515–520

    PubMed  CAS  Google Scholar 

  85. Romeo G, McKusick V (1994) Phenotypic diversity, alleic series and modifier genes. Nat.Genet 7:451–453

    PubMed  CAS  Google Scholar 

  86. Russo A, Zanna I, Tubiolo C, Migliavacca M, Bazan V, Latteri MA, Tomasino RM, Gebbia N (2000) Hereditary common cancers: molecular and clinical genetics. Anticancer Res 20(6C):4841–4851

    PubMed  CAS  Google Scholar 

  87. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M (2001) Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 61(4):1426–1431

    PubMed  CAS  Google Scholar 

  88. Sancandi M, Griseri P, Pesce B, Patrone G, Puppo F, Lerone M, Martucciello G, Romeo G, Ravazzolo R, Devoto M, Ceccherini I (2003) Single nucleotide polymorphic alleles in the 5′ region of the RET proto-oncogene define a risk haplotype in Hirschsprung’s disease. J Med Genet 40(9):714–718

    PubMed  CAS  Google Scholar 

  89. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G (1995) Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 133(5):513–522

    Article  PubMed  CAS  Google Scholar 

  90. Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 116(Pt 19):3855–3862

    PubMed  CAS  Google Scholar 

  91. Sasaki Y, Shimotake T, Go S, Iwai N (2001) Total thyroidectomy for hereditary medullary thyroid carcinoma 12 years after correction of Hirschsprung’s disease. Eur J Surg 167(6):467–469

    PubMed  CAS  Google Scholar 

  92. Schocket E, Telok HA (1957) Aganglionic megacolon, phaeochromocytoma, megaloureter and neurofibromatosis. Am J Dis Child 94:185–191

    Google Scholar 

  93. Schuchardt A, D’Agati V, Larsson-Blomberg L, Constanini F, Pachnis V (1994) Defects in the kidney and enteric system of mice lacking the tyrosine- kinase receptor ret. Nature 367:380–383

    PubMed  CAS  Google Scholar 

  94. Shocket E, Teloh HA (1957) Aganglionic megacolon, phaeochromocytoma, megaloureter and neurofibromatosis. Am J Dis Child 94:185–191

    CAS  Google Scholar 

  95. Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A, Aronson DC, Tan-Sindhunata G, Brouwers-Smalbraak GJ, Maas SM, Buys CH. (1998) Oncological implications of RET gene mutations in Hirschsprung’s disease. Gut 43(4):542–547

    PubMed  CAS  Google Scholar 

  96. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Jackson CE, Duncan AM, Farrer LA, Brasch K (1987) Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328(6130):528–530

    PubMed  CAS  Google Scholar 

  97. Sipple JH (1961) The association of phaeochromocytomas with carcinomas of the thyroid gland. Am J Med 31:163–166

    Google Scholar 

  98. Skaba R, Dvorakova S, Vaclavikova E, Vlcek P, Frantlova M, Bendlova B (2006) The risk of medullary thyroid carcinoma in patients with Hirschsprung’s disease. Pediatr Surg Int 22(12):991–995

    PubMed  Google Scholar 

  99. Skinner MA (2003) Management of hereditary thyroid cancer in children. Surg Oncol 12(2):101–104

    PubMed  Google Scholar 

  100. Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with phaeochromocytoma, medullary thyroid carcinoma, hyperparathyroidism, and Cushings disease:multiple endocrine neoplasia. Medicine (Baltimore) 47:371–409

    CAS  Google Scholar 

  101. Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42(2):581–588

    PubMed  CAS  Google Scholar 

  102. Takahishi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M (1999) Co-segregation of MEN2 and Hirschsprung’s disease: the same mutation with both gain and loss of function. Hum Mutat 13(4):331–336

    Google Scholar 

  103. Toledo SPA, Cortina MA, Toledo RA et al (2006) Impact of RET protooncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics 61:59–70

    PubMed  Google Scholar 

  104. Torre M, Martucciello G, Ceccherini I, Lerone M, Aicardi M, Gambini C, Jasonni V. (2002) Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients. Pediatr Surg Int 18(5–6):378–383

    PubMed  CAS  Google Scholar 

  105. van Heyningen V (1994) Genetics. One gene–four syndromes. Nature 367(6461):319–320

    PubMed  Google Scholar 

  106. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. (1982) Hirschsprung’s disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1(4):603–607

    Article  PubMed  CAS  Google Scholar 

  107. Williams ED, Pollock DJ (1966) Multiple mucosal neuromata with endocrine tumours:a syndrome allied to von Recklinghausens disease. J Pathol Bacteriol 91:71–80

    PubMed  CAS  Google Scholar 

  108. Wong A, Bogni S, Kotka P, de Graaff E, D’Agati V, Costantini F, Pachnis V (2005) Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 25(21):9661–9673

    PubMed  CAS  Google Scholar 

  109. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB (2003) Multiple endocrine neoplasia type 2: evaluation of the genotype–phenotype relationship. Arch Surg 138(4):409–416

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Paediatric Surgery, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, 7505, Tygerberg, South Africa

    S. W. Moore

  2. Department of Genetics, University of Stellenbosch, Cape Town, South Africa

    M. G. Zaahl

Authors
  1. S. W. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. G. Zaahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. W. Moore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, S.W., Zaahl, M.G. Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET. Pediatr Surg Int 24, 521–530 (2008). https://doi.org/10.1007/s00383-008-2137-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-008-2137-5

Keywords

Search

Navigation